Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nancy Daniels

Clinical Nurse Specialist, Psychiatric/Mental Health San Antonio, TX Clinical Nurse Specialist

NPI 1679664593 CMS profile 257587

9480 Huebner Road Suite 210, Suite 210, San Antonio, TX 78240

Open in the dashboard

General payments

$9,893

424 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nancy Daniels of San Antonio, TX is reported in the CMS Open Payments database as having received $9,893 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,349 58
2024 General $2,219 87
2023 General $2,375 103
2022 General $1,751 84
2021 General $2,199 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Daniels
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Nancy Daniels were reported at $1,349. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Nancy Daniels Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,199 $153 $44–$540 $132
2022 $1,751 $207 $60–$748 $149
2023 $2,375 $197 $55–$898 $160
2024 $2,219 $189 $49–$804 $164
2025 $1,349 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $839 38 payments
  2. Janssen Pharmaceuticals, Inc $835 22 payments
  3. Axsome Therapeutics, Inc. $823 26 payments
  4. Teva Pharmaceuticals USA, Inc. $817 23 payments
  5. ITI, Inc. $805 40 payments
  6. Neurocrine Biosciences, Inc. $804 31 payments
  7. Otsuka America Pharmaceutical, Inc. $673 41 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $579 30 payments
  9. Almatica Pharma LLC $499 27 payments
  10. Supernus Pharmaceuticals, Inc. $400 16 payments
  11. Other $2,818 130 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,846 423 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $839 38 payments
  2. SPRAVATO $715 21 payments
  3. Auvelity $712 21 payments
  4. INGREZZA $655 28 payments
  5. CAPLYTA $641 31 payments
  6. REXULTI $616 37 payments
  7. TRINTELLIX $579 30 payments
  8. LOREEV XR $499 27 payments
  9. QELBREE $382 15 payments
  10. LATUDA $322 20 payments
  11. Other $5,639 230 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

518

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$17,384

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

15.4%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aripiprazole Generic 29 $4,765
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 22 $2,125
Duloxetine Hcl Generic 36 $1,641
Clonazepam Generic 45 $1,303
Bupropion Xl Bupropion Hcl Brand 39 $1,247
Quetiapine Fumarate Generic 60 $1,115
Venlafaxine Hcl Er Venlafaxine Hcl Brand 19 $894
Ziprasidone Hcl Generic 13 $823
Oxcarbazepine Generic 17 $629
Lamotrigine Generic 22 $446

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$8,312

Medicare's payments for the services billed

Medicare patients

43

Average age 70

Services billed

132

30 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 72%
Arthritis 60%
Diabetes 33%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $284
$284 — —
CAPLYTA
  • ITI, Inc. $203
$203 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $201
$201 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $187
$187 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $160
$160 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record